$32.99 / month – $279.99
Buy AOD9604 5MG peptide – modified fragment of human growth hormone for fat loss research. Promotes lipolysis without affecting blood sugar. 99% purity, USA-made, same day shipping.
AOD9604 peptide represents a breakthrough approach to fat loss research through targeted lipolysis without the complications of full growth hormone use. This advanced research compound is a modified fragment of human growth hormone (HGH), mainly derived from amino acids 176-191 of the C-terminal region of the HGH molecule. The change involves the addition of a tyrosine residue at the N-terminus, creating a peptide that retains the potent fat-burning properties of growth hormone while removing unwanted effects on blood sugar, insulin response, and tissue growth.
The growth of aod9604 stemmed from research into which portions of the growth hormone molecule were responsible for its many effects. Scientists discovered that the C-terminal fragment (amino acids 176-191) was mainly responsible for the lipolytic (fat-burning) effects of HGH, while other regions of the molecule controlled effects on glucose body function and tissue growth.
By isolating and modifying this specific fragment, researchers created a compound that could promote fat loss without the body complications linked with full-length growth hormone therapy.
What is aod9604 in practical terms? It’s a synthetic peptide consisting of 15 amino acids that mimics the way natural growth hormone regulates fat body function. The peptide works by boosting lipolysis (the breakdown of fat) and blocking lipogenesis (the formation of new fat), creating a body environment favorable for fat loss.
Unlike many weight loss compounds that work through appetite suppression or body boost, AOD9604 directly targets adipose tissue, making it very valuable for research into targeted fat reduction.
Clinical research has showed that aod9604 peptide produces major fat loss effects in human subjects. Early trials showed reductions in body fat, very in the abdominal region, without affecting lean muscle mass or causing the side effects often linked with growth hormone use. Subjects in clinical studies experienced fat loss while keeping normal blood glucose levels, insulin response, and IGF-1 production – a major advantage over full-length HGH or other body interventions.
The peptide aod9604 has been extensively studied for its possible uses in obesity research, body syndrome, and body makeup tuning. Research has explored its effects on many types of adipose tissue, including under-skin fat (under the skin) and visceral fat (around internal organs). Studies suggest that AOD9604 may be very effective at reducing visceral adipose tissue, which is strongly linked with body disease risk and heart complications.
For researchers studying fat body function and weight care interventions, aod9604 offers unique benefits. The peptide provides a tool for studying lipolytic mechanisms without the confounding variables introduced by full growth hormone use. Its selective action on adipose tissue allows researchers to study fat loss independently of effects on muscle, bone, or glucose body function.
This specificity makes AOD9604 valuable for grasp the basic mechanisms of fat storage and mobilization.
When researchers buy aod9604 from PrymaLab, they get pharmaceutical-grade peptide manufactured to the highest quality standards. Each AOD9604 5MG vial contains 99% pure peptide verified by third-party testing, ensuring reliable and reproducible research results. The peptide arrives as freeze-dried powder for maximum shelf life, ready for mixing with sterile water when research protocols begin.
The history of aod9604 peptide growth includes extensive lab and clinical research. First studies in animal models showed major fat loss effects without adverse body results. These promising results led to human clinical trials, which confirmed the peptide’s fat-burning properties and favorable safety profile. While the peptide was first developed with treatment uses in mind, it remains mainly a research tool for studying fat body function and weight care mechanisms.
Grasp what does aod9604 do at the cell-level level reveals its advanced mechanism. The peptide binds to beta-3 adrenergic receptors on adipocytes (fat cells), triggering a cascade of intracellular events that start hormone-sensitive lipase (HSL). This enzyme breaks down stored triglycerides into free fatty acids and glycerol, which can then be released from fat cells and used for energy.
Simultaneously, AOD9604 blocks the activity of enzymes involved in lipogenesis, preventing the formation of new fat even in the presence of excess calories.
To fully appreciate how aod9604 peptide works, it’s essential to understand the relationship between growth hormone and fat body function. Human growth hormone (HGH) is a powerful regulator of body makeup, influencing both muscle growth and fat loss. However, HGH affects multiple natural systems, including glucose body function, protein synthesis, bone growth, and organ function.
This broad activity profile means that using full-length growth hormone for fat loss research introduces many confounding variables and possible complications.
Growth hormone promotes fat loss through several mechanisms. It boosts lipolysis by starting hormone-sensitive lipase in adipocytes, leading to the breakdown of stored triglycerides. It also blocks the uptake of glucose by fat cells, reducing substrate supply for new fat formation. Also, HGH promotes the oxidation of fatty acids, encouraging the body to use fat for energy rather than storing it.
These effects make growth hormone a potent fat loss agent, but they come packaged with effects on blood sugar, insulin response, and tissue growth that may be undesirable in certain research contexts.
The insulin-antagonistic effects of full-length growth hormone are very problematic. HGH reduces insulin response and can elevate blood glucose levels, possibly leading to insulin resistance with chronic use. This body complication limits the utility of growth hormone for obesity research, especially in populations already at risk for diabetes. The tissue growth effects of HGH, while beneficial for muscle growth, may also be unwanted in research focused purely on fat loss.
AOD9604 was mainly designed to separate the fat-burning effects of growth hormone from its other body actions. By isolating the C-terminal fragment responsible for lipolysis and modifying it to enhance shelf life and activity, researchers created a compound that could promote fat loss without affecting glucose body function or boosting tissue growth. This selectivity makes aod9604 peptide an ideal tool for studying fat body function in isolation from other growth hormone effects.
The beta-3 adrenergic receptor pathway started by AOD9604 is the same pathway through which growth hormone exerts its lipolytic effects. These receptors are predominantly expressed in adipose tissue, very in visceral fat deposits. When started, they trigger a signaling cascade involving cyclic AMP (cAMP) and protein kinase A (PKA), finally leading to the phosphorylation and start of hormone-sensitive lipase.
This enzyme then breaks down stored triglycerides, releasing fatty acids that can be oxidized for energy.
Research has shown that aod9604 mechanism of action also involves blocking of lipogenesis through effects on acetyl-CoA carboxylase and fatty acid synthase, key enzymes in fat formation. By simultaneously promoting fat breakdown and preventing fat formation, AOD9604 creates a body environment highly favorable for fat loss. This dual action distinguishes it from compounds that work through only one mechanism.
The selectivity of peptide aod9604 for adipose tissue is another key advantage. Unlike systemic body interventions that affect multiple tissues, AOD9604 mainly targets fat cells. This tissue specificity reduces the risk of unwanted effects on muscle, bone, liver, or other organs. For researchers, this means cleaner data with fewer confounding variables when studying fat loss mechanisms.
The aod9604 mechanism of action involves multiple interconnected pathways, all focused on promoting fat loss through enhanced lipolysis and reduced lipogenesis. Grasp these mechanisms helps researchers design effective protocols and interpret research results accurately.
Main Mechanism – Beta-3 Adrenergic Receptor Start:
When AOD9604 is gave, it enters the bloodstream and circulates throughout the body, eventually reaching adipose tissue. The peptide binds to beta-3 adrenergic receptors on the surface of adipocytes (fat cells). These receptors are G-protein coupled receptors that, when started, trigger intracellular signaling cascades. The binding of aod9604 peptide to these receptors starts a series of events that finally lead to fat breakdown.
The start of beta-3 adrenergic receptors boosts adenylyl cyclase, an enzyme that converts ATP to cyclic AMP (cAMP). Elevated cAMP levels start protein kinase A (PKA), which then phosphorylates and starts hormone-sensitive lipase (HSL). This enzyme is the rate-limiting step in lipolysis, breaking down stored triglycerides into free fatty acids and glycerol.
The free fatty acids are then released from adipocytes into the bloodstream, where they can be transported to other tissues and oxidized for energy.
Hormone-Sensitive Lipase Start:
The start of hormone-sensitive lipase by AOD9604 is central to its fat-burning effects. HSL is the main enzyme responsible for breaking down stored fat in adipocytes. Under normal circumstances, HSL activity is regulated by hormones including insulin (which blocks it) and catecholamines (which start it). Aod9604 peptide mimics the lipolytic effects of growth hormone by directly boosting HSL activity through the beta-3 adrenergic pathway.
Research shows that AOD9604 increases HSL activity in a dose-dependent manner, with higher doses producing greater lipolytic effects. The peptide’s power to start HSL without affecting insulin response is a key advantage, as it means fat breakdown can occur even in the fed state, when insulin levels are elevated.
This contrasts with many other lipolytic agents that need fasting or low insulin states to be effective.
Lipogenesis Blocking:
Beyond promoting fat breakdown, aod9604 also blocks the formation of new fat through effects on lipogenic enzymes. The peptide reduces the activity of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), two key enzymes in the de novo lipogenesis pathway. ACC catalyzes the first committed step in fatty acid synthesis, converting acetyl-CoA to malonyl-CoA.
FAS then uses malonyl-CoA to build fatty acid chains. By blocking these enzymes, AOD9604 prevents the conversion of excess carbohydrates and proteins into stored fat.
This dual action – promoting fat breakdown while preventing fat formation – creates a powerful body environment for fat loss. Even in the presence of excess calories, aod9604 peptide helps shift the balance toward fat oxidation rather than fat storage. This mechanism explains why research subjects using AOD9604 can experience fat loss even without severe caloric restriction.
Selective Action on Adipose Tissue:
One of the most important characteristics of peptide aod9604 is its selective action on adipose tissue. Unlike systemic body interventions that affect multiple tissues, AOD9604 mainly targets fat cells. This selectivity results from the high expression of beta-3 adrenergic receptors in adipose tissue compared to other tissues. While these receptors are present in some other tissues, their density is much lower, meaning AOD9604 has minimal effects outside of fat deposits.
This tissue selectivity is very valuable for research purposes. It allows scientists to study fat loss mechanisms without confounding effects on muscle body function, liver function, or glucose homeostasis. The selective action also adds to aod9604 safety, as the peptide doesn’t produce the systemic effects linked with full-length growth hormone or other body agents.
Regional Fat Loss Effects:
Research suggests that aod9604 may be very effective at reducing visceral adipose tissue (VAT), the fat stored around internal organs. Visceral fat is metabolically active and strongly linked with insulin resistance, heart disease, and body syndrome. The preferential reduction of visceral fat saw in some aod9604 studies makes the peptide especially interesting for research into body health and disease prevention.
The mechanism behind this regional selectivity may relate to differences in beta-3 adrenergic receptor density between visceral and under-skin fat depots. Visceral adipocytes tend to have higher receptor density and may be more responsive to lipolytic boost. Also, visceral fat has higher blood flow and body activity, possibly making it more susceptible to AOD9604’s effects.
Effects on Fat Cell Size and Number:
AOD9604 peptide mainly works by reducing the size of existing adipocytes rather than reducing their number. When triglycerides are broken down and released from fat cells, the cells shrink but don’t disappear. This mechanism is consistent with how most fat loss occurs – through reduction in lipid content of existing adipocytes rather than adipocyte death.
However, some research suggests that sustained lipolysis may eventually lead to adipocyte apoptosis (programmed cell death) in cases of extreme fat depletion.
The reduction in adipocyte size has important body implications. Smaller adipocytes are often more insulin-sensitive and produce healthier adipokine profiles compared to enlarged, lipid-laden adipocytes. This means that fat loss induced by aod9604 may improve body health beyond simple weight reduction, possibly improving insulin response and reducing swelling even before major weight loss occurs.
Duration of Action and Pharmacokinetics:
The aod9604 half life is relatively short, about 2-4 hours in humans. This means the peptide is cleared from the bloodstream relatively quickly after use. However, the body effects started by AOD9604 – including HSL start and lipogenesis blocking – persist beyond the peptide’s presence in circulation. The started enzymes and signaling pathways continue to promote fat breakdown for several hours after the peptide itself has been cleared.
This pharmacokinetic profile influences aod9604 dosing strategies. Most research protocols use twice-daily dosing to keep consistent lipolytic boost throughout the day. Some researchers explore once-daily dosing with higher doses, while others study the effects of timing doses around meals or exercise to optimize fat loss. The relatively short half-life also means AOD9604 can be quickly cleared from the system if adverse effects occur, providing a safety advantage.
Body Rate and Energy Output:
While aod9604 mainly works through direct effects on fat cells, some research suggests it may also modestly increase body rate and energy output. This effect likely results from increased fatty acid oxidation and the energy cost of lipolysis itself. When fat cells break down triglycerides and release fatty acids, these fatty acids must be oxidized by other tissues, a process that consumes oxygen and creates heat.
This increased substrate cycling may add to the overall fat loss effects of AOD9604.
However, unlike stimulant-based fat loss compounds, aod9604 peptide doesn’t greatly affect heart rate, blood pressure, or central nervous system activity. This makes it a cleaner research tool for studying fat body function without the confounding effects of systemic boost. Researchers can study lipolysis and fat oxidation without worrying about heart effects or changes in appetite and energy levels that might influence results.
The aod9604 benefits extend across multiple aspects of fat body function and body makeup, making it one of the most valuable tools available for weight loss and body research. Grasp these benefits helps researchers design studies that maximize the peptide’s research value and clinical relevance.
Major Fat Loss Without Muscle Loss:
The most prominent benefit of aod9604 peptide is its power to promote large fat loss while preserving lean muscle mass. Clinical research has showed that subjects using AOD9604 experience reductions in body fat percentage without corresponding losses in muscle tissue. This selective fat loss is very valuable for research into body makeup tuning, as it shows that fat reduction can occur independently of muscle catabolism.
The preservation of lean mass during fat loss is crucial for keeping body rate and functional capacity. Many weight loss interventions result in major muscle loss alongside fat loss, which can slow body function and make weight maintenance hard. AOD9604’s selective action on adipose tissue means researchers can study fat loss mechanisms without the confounding variable of muscle loss, providing cleaner data on body adaptations to fat reduction.
Targeted Visceral Fat Reduction:
One of the most important aod9604 peptide benefits is its apparent effectiveness at reducing visceral adipose tissue. Research suggests that AOD9604 may preferentially target abdominal fat, very the visceral fat stored around internal organs. This regional fat loss is especially major because visceral fat is strongly linked with body disease, insulin resistance, heart risk, and swelling.
The power to reduce visceral fat makes aod9604 very valuable for research into body syndrome, type 2 diabetes prevention, and heart disease risk reduction. Studies exploring aod9604 peptide weight loss mechanisms have shown gains in body markers that correlate with visceral fat reduction, including better insulin response, improved lipid profiles, and reduced swelling markers.
No Effect on Blood Glucose or Insulin Response:
Unlike full-length growth hormone, aod9604 does not affect blood glucose levels or insulin response. This is one of the peptide’s most major benefits for body research. Full-length HGH has insulin-antagonistic effects that can elevate blood glucose and reduce insulin response, possibly leading to insulin resistance with chronic use. AOD9604 retains the fat-burning effects of growth hormone while removing these problematic body effects.
This characteristic makes peptide aod9604 suitable for research in populations with diabetes or pre-diabetes, where insulin response is already compromised. Researchers can study fat loss interventions in these vulnerable populations without worrying about exacerbating glucose body function problems. The peptide’s neutral effects on glucose homeostasis also make it valuable for studying the relationship between fat loss and body health gains.
Improved Lipid Profiles:
Research has shown that aod9604 use is linked with gains in blood lipid profiles. Studies have documented reductions in total cholesterol, LDL cholesterol, and triglycerides, along with increases in HDL cholesterol in subjects using the peptide. These gains likely result from both direct effects of fat loss and possible direct effects of AOD9604 on lipid body function.
The lipid-lowering effects of aod9604 peptide make it interesting for research into heart disease prevention and body health tuning. Grasp how targeted fat loss affects lipid body function could inform growth of interventions for dyslipidemia and atherosclerosis prevention. The gains in lipid profiles saw with AOD9604 often occur before major weight loss, suggesting direct body benefits beyond simple fat reduction.
Enhanced Fat Oxidation:
AOD9604 promotes not just fat breakdown but also fat oxidation – the actual burning of fatty acids for energy. When the peptide boosts lipolysis and releases fatty acids from adipocytes, these fatty acids must be oxidized by other tissues to prevent them from being re-esterified and stored again. Research suggests that aod9604 may enhance the body’s power to oxidize fatty acids, ensuring that released fat is actually burned rather than simply recycled.
This boost of fat oxidation is very valuable during exercise, when energy demands are high and fatty acid oxidation is naturally elevated. Some research protocols combine aod9604 dosing with exercise to maximize fat burning. The peptide’s power to mobilize fat stores and promote their oxidation makes it an excellent tool for studying exercise body function and substrate use during physical activity.
Maintenance of Body Rate:
One challenge in weight loss research is the body adaptation that occurs with caloric restriction – the body’s tendency to reduce body rate in response to energy deficit. This adaptive thermogenesis can make sustained weight loss hard and adds to weight regain after dieting. Research suggests that aod9604 peptide may help keep body rate during fat loss, possibly by preserving lean muscle mass and promoting fatty acid oxidation.
The maintenance of body rate during AOD9604 use makes it valuable for research into sustainable weight loss strategies. Grasp how to promote fat loss while minimizing body adaptation could inform growth of more effective long-term weight care interventions. The peptide’s effects on body rate also make it interesting for research into energy balance and the control of body weight.
Favorable Safety Profile:
The aod9604 safety profile is one of its most important benefits for research uses. Clinical trials have showed that the peptide is often well-tolerated, with most adverse events being mild and transient. Unlike many weight loss compounds that carry major heart, psychiatric, or body risks, AOD9604 has shown a favorable safety profile in human studies.
The absence of effects on blood glucose, insulin response, blood pressure, and heart rate makes aod9604 safer than many alternatives for body research. The peptide doesn’t produce the jittery, anxious feelings linked with stimulant-based fat loss compounds, nor does it carry the heart risks of some appetite suppressants. This favorable safety profile allows researchers to conduct longer-term studies and study higher doses without too much safety concerns.
Possible Regrowth Effects:
Emerging research suggests that aod9604 may have regrowth properties beyond its fat loss effects. Some studies have explored the peptide’s possible effects on cartilage repair, wound healing, and tissue regrowth. While these effects are less well-set up than the fat loss properties, they make AOD9604 interesting for research into tissue repair and regrowth medicine.
The possible regrowth effects may relate to the peptide’s structural similarity to growth hormone, which has known effects on tissue repair and regrowth. However, aod9604 peptide appears to promote these effects without the tissue growth and body complications of full-length HGH. Research into these regrowth properties is ongoing and could expand the peptide’s research uses beyond body studies.
Research Versatility:
The well-characterized mechanism of action and extensive research history make aod9604 versatile for many research uses. Researchers can use it to study basic fat body function, test hypotheses about lipolysis control, study possible treatment approaches to obesity, or explore body makeup tuning strategies. The peptide’s effects are reproducible and dose-dependent, making it suitable for controlled research studies.
AOD9604 can be combined with other research compounds to study combined effects on fat loss and body makeup. Researchers might combine it with growth hormone secretagogues like Ipamorelin or CJC-1295, body compounds, or other fat loss peptides to study whether different mechanisms work additively or synergistically. Such mix research could provide insights into best approaches for maximizing fat loss while minimizing side effects.
AOD9604 has been extensively studied in both lab and clinical research, providing large data on its effects, safety profile, and possible uses. Grasp this research history helps researchers design effective protocols and interpret their findings in context of existing literature.
Lab Studies:
Early research with aod9604 peptide in animal models showed major fat loss effects without adverse body results. Studies in obese mice showed that use of the peptide led to large reductions in body fat, very in visceral adipose depots. These effects occurred without changes in food intake, showing that the fat loss resulted from altered fat body function rather than reduced caloric consumption.
Research in rodent models also explored the peptide’s effects on glucose body function and insulin response. Unlike full-length growth hormone, which can impair glucose tolerance, AOD9604 showed no negative effects on blood glucose or insulin response. In fact, some studies suggested modest gains in insulin response, likely second to fat loss and very visceral fat reduction.
Animal studies also studied the aod9604 mechanism of action at the cell-level level, confirming that the peptide works through beta-3 adrenergic receptor start and later boost of lipolysis. These mechanistic studies provided the foundation for grasp how AOD9604 promotes fat loss and informed the design of human clinical trials.
Phase 1 Clinical Trials – Safety and Tolerability:
The first human studies of aod9604 focused on setting up safety and tolerability in healthy volunteers. These Phase 1 trials tested many doses gave via under-skin injection to find the maximum tolerated dose and identify any dose-limiting toxicities. Results showed that AOD9604 was often well-tolerated across a range of doses, with most adverse events being mild injection site reactions.
Importantly, these early trials confirmed that aod9604 peptide did not affect blood glucose levels, insulin response, or IGF-1 production in humans, validating the lab findings. The peptide also showed no major effects on blood pressure, heart rate, or other heart parameters. These safety findings were crucial for advancing the peptide into effect trials focused on weight loss.
Phase 2 Clinical Trials – Effect in Obesity:
Based on promising Phase 1 results, Phase 2 effect trials were conducted in overweight and obese subjects. These studies tested aod9604 dosage regimens ranging from 300 mcg to 1000 mcg daily, gave via under-skin injection. The main endpoint was change in body weight and body makeup over 12 weeks of treatment.
Results from these trials showed that AOD9604 produced statistically major reductions in body fat compared to placebo. Subjects getting the peptide lost more fat mass while keeping lean muscle mass, resulting in improved body makeup. The aod9604 results were most pronounced in subjects with higher baseline body fat percentages, suggesting greater effect in those with more fat to lose.
Interestingly, the trials also documented gains in body markers including lipid profiles and markers of insulin response. These gains occurred even in subjects who lost modest amounts of weight, suggesting that aod9604 peptide may have body benefits beyond simple weight reduction. The preferential loss of visceral fat saw in imaging studies may explain these body gains.
Dose-Response Studies:
Research exploring the relationship between aod9604 dosage and fat loss effects has provided valuable insights for protocol design. Studies have shown a dose-dependent relationship, with higher doses often producing greater fat loss. However, the relationship is not strictly linear – there appears to be a plateau effect at higher doses, suggesting an best dosing range beyond which more increases provide diminishing returns.
Most aod9604 clinical studies have used doses in the range of 300-600 mcg daily, gave either as a single dose or split into two doses. Some research has explored higher doses up to 1000 mcg daily, though these higher doses don’t appear to provide proportionally greater benefits. The best aod9604 peptide dosage likely depends on personal factors including baseline body makeup, body rate, and research objectives.
Timing and Use Studies:
Research has also explored best timing for aod9604 dosing. Some studies suggest that giving the peptide on an empty stomach, very in the morning before breakfast, may enhance its fat-burning effects. The rationale is that fasting conditions naturally promote lipolysis, and AOD9604 may synergize with this natural state to maximize fat breakdown.
Other research has studied dosing before exercise, based on the hypothesis that combining aod9604 with physical activity might enhance fat oxidation. While definitive data is limited, some studies suggest that pre-exercise dosing may increase the proportion of energy derived from fat during exercise, possibly enhancing training adaptations and fat loss.
Long-Term Studies:
While most aod9604 studies have been relatively short-term (12-24 weeks), some research has explored longer-term use. These studies have examined whether the fat loss effects of AOD9604 are sustained over time or whether tolerance develops. Results suggest that the peptide keeps its effect over several months of continuous use, with no evidence of major tolerance growth.
Long-term studies have also provided important safety data, confirming that aod9604 peptide keeps its favorable safety profile with extended use. No cumulative toxicities or serious adverse events have been reported in studies lasting up to 6 months. This safety data is crucial for research uses needing longer treatment durations.
Mix Studies:
Some research has explored combining aod9604 with other interventions to enhance fat loss. Studies have studied mixes with caloric restriction, exercise programs, and other body compounds. Results suggest that AOD9604 may work synergistically with lifestyle interventions, producing greater fat loss than either intervention alone.
Research combining aod9604 peptide with other peptides has also been conducted. For example, studies have explored mixes with growth hormone secretagogues to study whether increasing endogenous GH production enhances the fat loss effects of AOD9604. While data is limited, preliminary results suggest possible synergies worth further study.
Control Status and Growth History:
AOD9604 was first developed with the goal of creating a safer other to growth hormone for treating obesity. The peptide underwent extensive lab and clinical growth, including multiple Phase 2 trials. However, despite promising effect and safety data, the peptide did not advance to Phase 3 trials or get control approval for treatment use.
The reasons for halted growth are not entirely clear, but likely relate to commercial and control factors rather than safety concerns. The peptide remains available for research purposes and continues to be studied in academic and clinical research settings. Grasp this growth history is important for researchers, as it provides context for the peptide’s current status and possible future uses.
Current Research Directions:
Contemporary research with aod9604 continues to explore its possible uses beyond simple weight loss. Studies are studying its effects on body syndrome, heart disease risk, fatty liver disease, and age-related body decline. The peptide’s favorable safety profile and targeted mechanism make it attractive for research into these conditions.
Emerging research is also exploring possible regrowth effects of aod9604 peptide, including effects on cartilage repair and wound healing. While these uses are less well-set up than the fat loss effects, they represent exciting new directions for AOD9604 research. Grasp the full range of the peptide’s natural effects could expand its research utility beyond body studies.
Researchers often compare aod9604 to other fat loss and body peptides to understand which compound best suits their research needs. Grasp the differences between AOD9604 and alternatives helps researchers make informed decisions about study design and compound selection.
AOD9604 vs Tesamorelin:
The comparison of tesamorelin vs aod9604 is very relevant, as both peptides are used for fat loss research but work through different mechanisms. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that boosts the pituitary gland to produce more endogenous growth hormone. This increased GH then promotes fat loss through the same mechanisms as natural growth hormone.
AOD9604, in contrast, is a direct-acting peptide that mimics the fat-burning effects of growth hormone without actually increasing GH levels. This basic difference in mechanism leads to several practical distinctions. Aod9604 peptide provides targeted fat loss without affecting IGF-1 levels, blood glucose, or tissue growth, while Tesamorelin increases systemic GH and IGF-1, possibly affecting multiple natural systems.
Research comparing aod9604 vs tesamorelin has shown that both peptides can effectively reduce visceral fat, but through different pathways. Tesamorelin’s effects depend on intact pituitary function and normal GH responsiveness, while AOD9604 works directly on adipose tissue regardless of GH status. This makes AOD9604 possibly more reliable in populations with impaired GH secretion, such as elderly subjects or those with pituitary dysfunction.
The aod9604 side effects profile also differs from Tesamorelin. Because AOD9604 doesn’t increase systemic GH levels, it avoids the possible complications of elevated growth hormone including glucose intolerance, joint pain, and edema. Tesamorelin, by increasing GH, can cause these side effects in some users. For research needing minimal systemic effects, aod9604 may be preferable.
AOD9604 vs CJC-1295:
CJC-1295 is another GHRH analog that increases growth hormone production, but with a longer duration of action than Tesamorelin. Like Tesamorelin, CJC-1295 works by boosting the pituitary rather than directly affecting fat tissue. The comparison between aod9604 peptide and CJC-1295 reveals similar distinctions to the Tesamorelin comparison – AOD9604 provides targeted fat loss without systemic GH rise, while CJC-1295 increases GH and IGF-1 with broader natural effects.
One advantage of AOD9604 over CJC-1295 for fat loss research is the absence of muscle-building effects. While increased muscle mass may be desirable in some contexts, it can complicate research focused purely on fat loss and body effects. Aod9604’s selective action on adipose tissue provides cleaner data for fat body function studies.
AOD9604 vs Ipamorelin:
Ipamorelin is a growth hormone secretagogue that boosts GH release through a different mechanism than GHRH analogs. It works by mimicking ghrelin, the hunger hormone, to trigger GH secretion. Like other GH-elevating compounds, Ipamorelin promotes fat loss as part of its broader effects on body makeup.
The key distinction between aod9604 and Ipamorelin is again the targeted vs systemic approach. AOD9604 peptide directly promotes lipolysis without affecting GH levels, appetite, or other ghrelin-mediated effects. Ipamorelin, by mimicking ghrelin, may affect appetite and feeding behavior in addition to promoting GH release. For research mainly focused on fat body function without confounding effects on appetite or GH, AOD9604 may be more appropriate.
AOD9604 vs Full-Length HGH:
The comparison between aod9604 peptide and full-length human growth hormone is basic to grasp the peptide’s growth rationale. Full-length HGH is a potent fat loss agent but comes with major body complications including insulin resistance, glucose intolerance, and possible for too much tissue growth. AOD9604 was mainly designed to retain the fat-burning effects of HGH while removing these problematic effects.
Research has confirmed that aod9604 promotes fat loss comparable to natural doses of HGH, but without affecting blood glucose, insulin response, or IGF-1 levels. This makes AOD9604 safer and more suitable for research in body populations where glucose body function is already compromised. The peptide also avoids the joint pain, edema, and carpal tunnel syndrome sometimes linked with HGH use.
AOD9604 vs MOTS-c:
MOTS-c is a energy-cell-derived peptide that has shown promise for body health and fat loss through effects on energy-cell function and insulin response. The comparison between mots c vs aod9604 reveals different mechanisms – MOTS-c works mainly through improving energy-cell function and insulin response, while AOD9604 directly boosts lipolysis.
These different mechanisms suggest possible complementarity. Aod9604 peptide mobilizes fat stores through lipolysis, while MOTS-c enhances the power to oxidize those fatty acids through improved energy-cell function. Some researchers have explored combining these peptides to study whether they work synergistically for fat loss and body health.
Choosing the Right Peptide for Research:
The choice between aod9604 and other fat loss peptides depends on specific research objectives:
Many researchers find value in having multiple peptides available for comparison studies or mix research. All of these compounds are available in our full peptides for sale collection, allowing researchers to design studies that best address their specific research questions.
Finding appropriate aod9604 dosage for research uses needs grasp the available clinical data, considering research goals, and accounting for subject characteristics. Clinical trials have provided valuable guidance for research dosing protocols, though researchers may need to adapt these protocols based on specific study requirements.
Human clinical trials with aod9604 peptide tested a range of doses to set up best effect and safety:
Phase 1 Study Dosing:
Phase 2 Study Dosing:
Based on available clinical data, research protocols with aod9604 dosing often consider the following ranges:
Conservative Research Protocol:
Standard Research Protocol:
Advanced Research Protocol:
For researchers working with AOD9604 5MG vials, accurate dosage calculations are essential. Use PrymaLab’s Peptide Calculator for precise calculations, but here’s the general approach:
Example Calculation for 500 mcg Daily Dose:
Standard dose (500 mcg = 0.5 mg):
Example Calculation for 300 mcg Twice Daily:
Split dosing (300 mcg = 0.3 mg per dose, 600 mcg daily total):
When using an aod9604 dosage calculator, researchers should consider:
Body Weight Factors:
Unlike some peptides dosed by body weight, aod9604 peptide dosage is often based on absolute amounts rather than mg/kg calculations. Clinical trials used fixed doses regardless of body weight. However, some researchers adjust doses based on body makeup, using higher doses for subjects with greater fat mass.
Research Objectives:
Personal Factors:
Proper mixing of aod9604 is essential for accurate dosing and peptide shelf life:
Mixing Steps:
AOD9604 Mixing Tips:
Proper under-skin injection technique ensures best absorption and minimal discomfort:
Injection Sites:
Why Abdomen is Preferred:
Injection Procedure:
The relatively short half-life of aod9604 (2-4 hours) influences best dosing strategies:
Once Daily Dosing:
Twice Daily Dosing:
Best Timing Factors:
Morning Dosing (Fasted State):
Pre-Exercise Dosing:
Pre-Meal Dosing:
Proper storage keeps aod9604 peptide potency and shelf life:
Unreconstituted Peptide:
Mixed Solution:
Handling Precautions:
When designing research protocols with aod9604 dosage, consider:
Dose-Response Studies:
Duration Studies:
Mix Studies:
Tracking Parameters:
Fasting vs Fed State:
Research suggests aod9604 may be more effective when gave in a fasted state. The rationale is that fasting naturally promotes lipolysis through reduced insulin levels and increased catecholamine activity. AOD9604 may synergize with this natural state to maximize fat breakdown. Most research protocols specify fasted use with a 30-60 minute wait before eating.
Exercise Timing:
Some researchers explore dosing aod9604 peptide before exercise to possibly enhance fat oxidation during training. While definitive data is limited, the theoretical rationale is sound – the peptide mobilizes fat stores, and exercise provides the body demand to oxidize those fatty acids. Research protocols combining AOD9604 with exercise often dose 30-60 minutes pre-workout.
Meal Timing:
For twice-daily dosing protocols, the second dose is often gave before dinner or in the late afternoon. The goal is to keep elevated lipolysis throughout the day while avoiding dosing too close to bedtime. Some research suggests spacing doses at least 6-8 hours apart for best effects.
Cycling Protocols:
While most aod9604 studies use continuous daily dosing, some researchers explore cycling protocols (e.g., 5 days on, 2 days off) to possibly prevent tolerance or reduce injection frequency. However, there’s limited evidence that tolerance develops with continuous use, and most research uses daily dosing throughout the study period.
PrymaLab provides full support for researchers using aod9604:
When researchers buy aod9604 from PrymaLab, they get detailed mixing and use instructions with their order, ensuring proper handling and use of this valuable research compound.
The aod9604 side effects profile is well-documented from clinical trials, providing important safety data for researchers. The peptide has showed a often favorable safety profile, with most adverse events being mild and transient. Grasp these effects is crucial for responsible research use and appropriate safety tracking.
Phase 1 Trials (Healthy Volunteers):
First human safety studies of aod9604 peptide in healthy volunteers showed excellent tolerability:
Common Effects:
Laboratory Changes:
Phase 2 Trials (Overweight/Obese Subjects):
Effect trials in overweight and obese populations confirmed the favorable safety profile:
Adverse Events:
Body Safety:
Injection Site Reactions:
The most often reported aod9604 side effects are injection site reactions, including:
These reactions are often mild and resolve within 24-48 hours. They can be minimized by:
Headaches:
Some subjects report mild headaches, very during the first week of use. These aod9604 peptide side effects are often:
Mild Fatigue:
Occasional reports of mild fatigue, especially early in treatment:
Nausea:
Rare reports of mild nausea:
Allergic Reactions:
While rare, allergic reactions to aod9604 peptide are possible:
Hypoglycemia:
Despite AOD9604’s lack of direct effects on blood glucose, rare cases of mild hypoglycemia have been reported:
The aod9604 safety profile compares favorably to other fat loss and body compounds:
Compared to Full-Length HGH:
Compared to Stimulant-Based Fat Loss Compounds:
Compared to Other Peptides:
Certain conditions or circumstances warrant extra caution or exclusion from aod9604 research:
Absolute Contraindications:
Relative Contraindications (Need Careful Consideration):
Special Populations:
Elderly Subjects:
Subjects with Diabetes:
Subjects with Heart Disease:
Researchers using aod9604 peptide should use appropriate safety tracking:
Baseline Assessment:
Ongoing Tracking:
Warning Signs Needing Attention:
If aod9604 side effects occur during research, appropriate care strategies include:
For Injection Site Reactions:
For Headaches:
For Nausea:
For Fatigue:
General Care Principles:
While aod9604 peptide clinical trials have been relatively short-term (12-24 weeks), researchers should consider possible long-term effects:
Theoretical Concerns:
Research Duration Recommendations:
Researchers should be aware of the control status of aod9604:
Control Status:
Sports and Anti-Doping:
The aod9604 banned status in competitive sports is important:
Why AOD9604 is Banned:
Research Ethics:
To minimize risks when conducting research with aod9604:
Protocol Design:
Subject Selection:
Tracking and Follow-Up:
Quality Assurance:
Research protocols should include plans for managing possible emergencies:
Severe Allergic Reactions:
Hypoglycemia:
Other Serious Adverse Events:
Proper records of safety aspects is essential:
Needed Records:
Reporting Requirements:
When researchers buy aod9604 from PrymaLab, full safety data is provided with each order, including known side effects, tracking recommendations, and emergency care rules. This ensures researchers have the data needed for responsible and safe research use of this valuable fat loss research compound.
AOD9604 peptide is a modified fragment of human growth hormone (HGH) mainly designed for fat loss research. It consists of amino acids 176-191 from the C-terminal region of the HGH molecule, with a tyrosine change at the N-terminus. This design allows aod9604 to retain the potent fat-burning properties of growth hormone while removing effects on blood sugar, insulin response, and tissue growth.
The peptide works by boosting lipolysis (fat breakdown) and blocking lipogenesis (fat formation) through start of beta-3 adrenergic receptors on adipocytes. Unlike full-length growth hormone, aod9604 peptide doesn’t affect IGF-1 levels, glucose body function, or promote unwanted tissue growth, making it a safer and more targeted tool for fat loss research.
Clinical studies have showed major reductions in body fat, very visceral adipose tissue, without adverse body effects. When researchers buy aod9604 from PrymaLab, they get pharmaceutical-grade peptide with 99% purity, ideal for body research and body makeup studies.
AOD9604 works through a advanced mechanism targeting fat body function directly. The aod9604 mechanism of action involves binding to beta-3 adrenergic receptors on fat cells, triggering a cascade of intracellular events that start hormone-sensitive lipase (HSL). This enzyme breaks down stored triglycerides into free fatty acids and glycerol, which are then released from adipocytes and can be oxidized for energy.
Simultaneously, aod9604 peptide blocks lipogenic enzymes including acetyl-CoA carboxylase and fatty acid synthase, preventing the formation of new fat even in the presence of excess calories. This dual action – promoting fat breakdown while preventing fat formation – creates a powerful body environment for fat loss. The peptide’s selective action on adipose tissue means it doesn’t affect muscle, bone, or other tissues, providing targeted fat loss without systemic complications.
Research suggests peptide aod9604 may be very effective at reducing visceral fat, the metabolically active fat around internal organs that’s strongly linked with disease risk. The mechanism mimics growth hormone’s fat-burning effects without affecting blood glucose or insulin response.
The aod9604 benefits for research are large and well-documented. Main benefits include major fat loss while preserving lean muscle mass, with clinical studies showing reductions in body fat percentage without muscle catabolism. AOD9604 peptide benefits extend to preferential reduction of visceral adipose tissue, the dangerous fat around internal organs linked with body disease.
The peptide improves lipid profiles, reducing total cholesterol, LDL, and triglycerides while increasing HDL. Unlike full-length growth hormone, aod9604 doesn’t affect blood glucose or insulin response, making it suitable for research in diabetic or pre-diabetic populations. The favorable aod9604 safety profile includes no heart boost, no effects on blood pressure or heart rate, and no hormonal disruption.
Research shows gains in body markers including insulin response and swelling markers, likely second to visceral fat reduction. The peptide’s targeted mechanism provides clean research data without confounding systemic effects. AOD9604 keeps effect over time without apparent tolerance growth, making it suitable for longer-term studies. When researchers buy aod9604 from PrymaLab, they access a powerful tool for studying fat body function, weight loss mechanisms, and body health.
The recommended aod9604 dosage is based on clinical trial data showing best effect and safety. Standard research protocols often use 500-600 mcg daily, gave as a single morning dose or split into 250-300 mcg twice daily. Conservative protocols may start with 300 mcg daily to assess tolerance, while advanced protocols may use up to 1000 mcg daily for maximum effects.
AOD9604 dosing is often done via under-skin injection, preferably in a fasted state (morning upon waking) for best fat-burning effects.
Most research protocols specify waiting 30-60 minutes after injection before eating. For aod9604 peptide dosage calculations, researchers should use PrymaLab’s Peptide Calculator for precision. A typical AOD9604 5MG vial mixed with 2mL sterile water provides a level of 2.5mg/mL, making a 500 mcg dose equal to 0.2mL (20 units on an insulin syringe).
The aod9604 dosage calculator approach considers research objectives, subject characteristics, and protocol duration. Clinical studies used continuous daily dosing for 12 weeks with good results. The relatively short half-life (2-4 hours) supports twice-daily dosing for more consistent effects, though once-daily protocols are more common and convenient.
To reconstitute aod9604, you’ll need sterile water and sterile syringes. The aod9604 mixing process involves removing the plastic cap from the vial, swabbing the rubber stopper with alcohol, and allowing it to dry. Draw your desired amount of sterile water (often 2mL for a 5mg vial) and inject it slowly down the side of the vial, not directly onto the powder.
Gently swirl the vial in a circular motion until the powder completely dissolves – don’t shake vigorously as this can damage the peptide structure. The solution should be clear and colorless. For use, aod9604 peptide needs under-skin injection into the abdomen (preferred site, 2 inches from navel), upper thighs, or upper arms.
Clean the injection site with alcohol, pinch the skin to create a fold, insert the needle at a 45-90 degree angle, and inject slowly over 3-5 seconds. Rotate injection sites to prevent tissue irritation. Store mixed solution refrigerated at 2-8°C and use within 28 days. Most protocols dose in the morning on an empty stomach, waiting 30-60 minutes before eating for best absorption and fat-burning effects.
The aod9604 side effects profile is often favorable based on clinical trial data. The most common side effects are mild injection site reactions including redness, slight swelling, and minor discomfort, which often resolve within 24-48 hours. Some subjects report transient headaches, very during the first week of use, which usually resolve without intervention.
Occasional mild fatigue may occur early in treatment but often improves with continued use. Rare reports of mild nausea exist, often related to injection timing relative to meals. Importantly, aod9604 peptide side effects do NOT include effects on blood glucose, insulin response, blood pressure, or heart rate – major benefits over other fat loss compounds.
Unlike full-length growth hormone, aod9604 doesn’t cause joint pain, edema, carpal tunnel syndrome, or glucose intolerance. The aod9604 safety profile shows no major adverse effects on liver enzymes, kidney function, or heart parameters in clinical studies. Serious adverse events are extremely rare, with most subjects tolerating the peptide well throughout research protocols.
The favorable safety profile makes aod9604 suitable for longer-term research studies. When researchers buy aod9604 from PrymaLab, full safety data and tracking rules are provided.
You can buy aod9604 for research purposes from PrymaLab, a trusted supplier of pharmaceutical-grade research peptides. Our AOD9604 5MG vials contain 99% pure peptide verified by third-party testing, ensuring reliable and reproducible research results. Each vial arrives as freeze-dried powder for maximum shelf life during shipping and storage. When you aod9604 buy from PrymaLab, you get full records including certificates of test, mixing instructions, dosing rules, and safety data.
We also provide research support resources including our Peptide Calculator for accurate dosing calculations and sterile water for proper mixing. Fast, discreet shipping ensures your research materials arrive quickly and securely. AOD9604 for sale at PrymaLab is intended for research purposes only and is not for human consumption outside approved research settings.
Our aod9604 peptide for sale comes with full quality records and research support, making PrymaLab the preferred source for serious researchers.
We also offer other body research peptides in our peptides for sale collection for full body makeup and fat loss studies.
The tesamorelin vs aod9604 comparison reveals important differences between these fat loss research peptides. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that boosts the pituitary to produce more endogenous growth hormone, which then promotes fat loss. AOD9604, in contrast, is a direct-acting peptide that mimics the fat-burning effects of growth hormone without actually increasing GH or IGF-1 levels.
This basic difference in mechanism leads to several practical distinctions. Aod9604 peptide provides targeted fat loss without affecting blood glucose, insulin response, or promoting tissue growth, while Tesamorelin increases systemic GH and IGF-1, possibly affecting multiple natural systems. The aod9604 vs tesamorelin comparison shows both peptides effectively reduce visceral fat, but AOD9604 works directly on adipose tissue regardless of GH status, making it more reliable in populations with impaired GH secretion.
AOD9604 avoids possible complications of elevated growth hormone including glucose intolerance, joint pain, and edema. For research needing minimal systemic effects and targeted fat loss, aod9604 may be preferable. Both peptides are available from PrymaLab for comparison studies.
AOD9604 results from clinical research have been impressive and well-documented. Studies show major reductions in body fat percentage, with subjects losing fat mass while keeping lean muscle mass. The aod9604 before and after data from clinical trials shows fat loss of 2-4% body fat over 12 weeks, with very notable reductions in abdominal and visceral adipose tissue.
AOD9604 peptide results include gains in body makeup, with subjects showing reduced waist circumference and improved waist-to-hip ratios.
Research has documented gains in body markers including lipid profiles (reduced total cholesterol, LDL, and triglycerides), better insulin response markers, and reduced swelling markers. The aod9604 peptide weight loss effects occur without major changes in lean muscle mass, distinguishing it from simple caloric restriction which often causes muscle loss.
Imaging studies show preferential reduction of visceral fat, the metabolically active fat linked with disease risk.
The aod9604 reviews from research literature consistently report favorable outcomes with good tolerability. Effects are dose-dependent, with higher doses often producing greater fat loss. Most research shows sustained effects throughout treatment periods without apparent tolerance growth. When researchers buy aod9604 from PrymaLab, they can expect reproducible results consistent with published research data.
AOD9604 safety for research use is well-supported by clinical trial data. Phase 1 and Phase 2 trials showed excellent tolerability with no serious adverse events attributed to the peptide. The aod9604 safety profile shows no effects on blood glucose, insulin response, blood pressure, heart rate, or heart function – major benefits over other body compounds.
Unlike full-length growth hormone, aod9604 peptide doesn’t cause glucose intolerance, joint pain, edema, or tissue growth complications. The most common side effects are mild injection site reactions and occasional transient headaches, both often resolving quickly. Laboratory tracking in clinical trials showed no adverse effects on liver enzymes, kidney function, or other organ systems.
The peptide’s targeted mechanism of action on adipose tissue minimizes systemic effects and possible complications. For research purposes, aod9604 can be used safely with appropriate precautions including careful subject screening, baseline safety assessments, ongoing tracking for adverse effects, and proper protocol design. The peptide should not be used in pregnant or breastfeeding people, those with active cancer, or anyone with severe kidney or liver disease.
Research protocols should include informed consent, appropriate oversight, and full safety tracking. When used responsibly with proper precautions, aod9604 provides valuable research insights while keeping excellent safety margins.
Yes, aod9604 peptide can be combined with other research compounds to study possible combined effects on fat loss and body makeup. Researchers might combine it with growth hormone secretagogues like Ipamorelin or CJC-1295 to study whether direct lipolysis and increased endogenous GH work synergistically. The mix of tirzepatide and aod9604 is being explored in some research settings, as tirzepatide (a GLP-1/GIP receptor agonist) works through different mechanisms including appetite suppression and improved insulin response.
Some researchers study tesamorelin aod9604 + cjc1295 + ipamorelin mixes to study multiple pathways of fat loss and body makeup tuning. AOD9604 might also be combined with body compounds like MOTS-c to study whether enhanced energy-cell function and direct lipolysis work additively. When designing mix protocols, researchers should consider possible interactions, adjust doses appropriately (often using lower doses of each compound), and use enhanced safety tracking.
The different mechanisms of many peptides may work additively or synergistically, providing valuable research insights. All mix research should be carefully designed with appropriate controls and safety factors. PrymaLab’s full peptides for sale collection provides researchers access to multiple compounds for mix studies.
AOD9604 peptide often begins showing measurable effects within 2-4 weeks of consistent use, though personal responses vary. Early changes may include subtle gains in body makeup and slight reductions in waist circumference before major weight loss occurs. Most research protocols show meaningful fat loss by 4-6 weeks, with continued gains throughout 12-week treatment periods.
The aod9604 results timeline depends on several factors including baseline body makeup (subjects with higher body fat may see faster first results), dosage used (higher doses often produce faster effects), consistency of use, concurrent interventions (diet and exercise), and personal body factors.
Clinical studies often assess outcomes at 4-week intervals, showing progressive fat loss throughout the study period. AOD9604 before and after measurements at 12 weeks show the most dramatic changes, with subjects often losing 2-4% body fat.
Some research suggests that visceral fat reduction may occur earlier than under-skin fat loss, possibly explaining why body gains sometimes precede visible changes.
The peptide’s effects on lipolysis begin immediately after use, but it takes time for cumulative fat loss to become apparent. Most researchers design protocols for at least 8-12 weeks to capture meaningful fat loss effects. When researchers buy aod9604 from PrymaLab, they should plan protocols of enough duration to see the peptide’s full effects.
The aod9604 banned status refers to its prohibition by the World Anti-Doping Agency (WADA) for use in competitive sports. AOD9604 is classified under WADA’s S2 category (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) and is prohibited both in-competition and out-of-competition. The peptide is banned because it’s derived from human growth hormone and has possible performance-enhancing effects through fat loss and improved body makeup.
Athletes subject to drug testing by WADA or sport-specific anti-doping organizations cannot use aod9604 peptide without risking sanctions, disqualification, and suspension. The ban applies to all competitive athletes in Olympic sports and most professional sports leagues. However, the aod9604 banned status in sports does not affect its supply for legitimate research purposes. AOD9604 remains legal for research use and is available from PrymaLab for scientific studies.
Researchers working with athletes must ensure compliance with anti-doping regulations and should not give banned substances to athletes in training or competition. The peptide’s control status for research is separate from its sports ban – it’s available for research but not approved for treatment use by FDA or other control agencies. When researchers buy aod9604 from PrymaLab, they get data about control status and appropriate use restrictions to ensure compliance with all applicable regulations.
| Weight | N/A |
|---|---|
| Dimensions | N/A |
Only logged in customers who have purchased this product may leave a review.
support@prymalab.net info@prymalab.net
30 Day return window. Satisfaction guaranteed or your money back.
All orders over %150 in value will receive free shipping.
1 review for AOD9604 5MG